Redmile Biopharma Investments II, L.P.

549300FQJPFVEU9NE257

The entity

Status: Active
LEI status: Issued and current
Category: Fund
Legal form: Limited Partnership (T91T)
Jurisdiction: US-DE
Entity created: October 1, 2018

Address

Country: United States
Legal address: C/O CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE19808 WILMINGTONUnited States (US-DE)
Head office: C/O REDMILE GROUP, LLC, One Letterman Drive, Building D, Suite D3-30094129 San FranciscoUnited States (US-CA)

Identifier

LEI: 549300FQJPFVEU9NE257
Registered: October 28, 2022 at 09:29 PM UTC
Last updated: April 1, 2026 at 05:13 PM UTC
Next renewal: December 24, 2026 at 01:03 PM UTC
Issuer: Bloomberg (5493001KJTIIGC8Y1R12)
Registered with: Division of Corporations, Department of State (RA000602)
Identifier: 7081647
Verified against: EDGAR (RA000665)
Verified as: 0001772230
Corroboration: Confirmed against a public register
GLEIF conformity: Meets the standard

Corporate structure

Owned by

REDMILE GROUP, LLC
Fund managerUnited States5493007T2I6TUUZ37I60

Why no parent is reported

No direct parent reportedNo ultimate parent reported: No parent prepares consolidated accounts including it

Machine access

REST: https://lei.online/v1/entities/549300FQJPFVEU9NE257This record as JSON.
MCP: https://lei.online/mcpThe same data as an MCP tool.

Start a new search